CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Technological advancements in the ocular drug delivery
3.4.1.2. Surge in prevalence of eye disorders
3.4.1.3. Rise in geriatric population
3.4.2. Restraints
3.4.2.1. Stringent regulatory requirements for product approvals
3.4.3. Opportunities
3.4.3.1. Surge in new product approvals and strong product pipeline
CHAPTER 4: OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY
4.1. Overview
4.1.1. Market size and forecast
4.2. Topical
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Ocular Insert
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Intraocular Implants
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. In-Situ Gel
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Others
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
CHAPTER 5: OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Solution
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Emulsion
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Suspension
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Ointment
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Others
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
CHAPTER 6: OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Glaucoma
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Diabetic Retinopathy
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Dry Eye Syndrome
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Age related macular degeneration
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
6.6. Others
6.6.1. Key market trends, growth factors and opportunities
6.6.2. Market size and forecast, by region
6.6.3. Market share analysis by country
CHAPTER 7: OCULAR DRUG DELIVERY MARKET, BY END USER
7.1. Overview
7.1.1. Market size and forecast
7.2. Hospitals
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Ophthalmic Clinics
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Others
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: OCULAR DRUG DELIVERY MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast, by Technology
8.2.3. Market size and forecast, by Formulation Type
8.2.4. Market size and forecast, by Disease Indication
8.2.5. Market size and forecast, by End User
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Market size and forecast, by Technology
8.2.6.1.2. Market size and forecast, by Formulation Type
8.2.6.1.3. Market size and forecast, by Disease Indication
8.2.6.1.4. Market size and forecast, by End User
8.2.6.2. Canada
8.2.6.2.1. Market size and forecast, by Technology
8.2.6.2.2. Market size and forecast, by Formulation Type
8.2.6.2.3. Market size and forecast, by Disease Indication
8.2.6.2.4. Market size and forecast, by End User
8.2.6.3. Mexico
8.2.6.3.1. Market size and forecast, by Technology
8.2.6.3.2. Market size and forecast, by Formulation Type
8.2.6.3.3. Market size and forecast, by Disease Indication
8.2.6.3.4. Market size and forecast, by End User
8.3. Europe
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast, by Technology
8.3.3. Market size and forecast, by Formulation Type
8.3.4. Market size and forecast, by Disease Indication
8.3.5. Market size and forecast, by End User
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Market size and forecast, by Technology
8.3.6.1.2. Market size and forecast, by Formulation Type
8.3.6.1.3. Market size and forecast, by Disease Indication
8.3.6.1.4. Market size and forecast, by End User
8.3.6.2. France
8.3.6.2.1. Market size and forecast, by Technology
8.3.6.2.2. Market size and forecast, by Formulation Type
8.3.6.2.3. Market size and forecast, by Disease Indication
8.3.6.2.4. Market size and forecast, by End User
8.3.6.3. UK
8.3.6.3.1. Market size and forecast, by Technology
8.3.6.3.2. Market size and forecast, by Formulation Type
8.3.6.3.3. Market size and forecast, by Disease Indication
8.3.6.3.4. Market size and forecast, by End User
8.3.6.4. Italy
8.3.6.4.1. Market size and forecast, by Technology
8.3.6.4.2. Market size and forecast, by Formulation Type
8.3.6.4.3. Market size and forecast, by Disease Indication
8.3.6.4.4. Market size and forecast, by End User
8.3.6.5. Spain
8.3.6.5.1. Market size and forecast, by Technology
8.3.6.5.2. Market size and forecast, by Formulation Type
8.3.6.5.3. Market size and forecast, by Disease Indication
8.3.6.5.4. Market size and forecast, by End User
8.3.6.6. Rest of Europe
8.3.6.6.1. Market size and forecast, by Technology
8.3.6.6.2. Market size and forecast, by Formulation Type
8.3.6.6.3. Market size and forecast, by Disease Indication
8.3.6.6.4. Market size and forecast, by End User
8.4. Asia-Pacific
8.4.1. Key market trends, growth factors and opportunities
8.4.2. Market size and forecast, by Technology
8.4.3. Market size and forecast, by Formulation Type
8.4.4. Market size and forecast, by Disease Indication
8.4.5. Market size and forecast, by End User
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Market size and forecast, by Technology
8.4.6.1.2. Market size and forecast, by Formulation Type
8.4.6.1.3. Market size and forecast, by Disease Indication
8.4.6.1.4. Market size and forecast, by End User
8.4.6.2. China
8.4.6.2.1. Market size and forecast, by Technology
8.4.6.2.2. Market size and forecast, by Formulation Type
8.4.6.2.3. Market size and forecast, by Disease Indication
8.4.6.2.4. Market size and forecast, by End User
8.4.6.3. India
8.4.6.3.1. Market size and forecast, by Technology
8.4.6.3.2. Market size and forecast, by Formulation Type
8.4.6.3.3. Market size and forecast, by Disease Indication
8.4.6.3.4. Market size and forecast, by End User
8.4.6.4. Australia
8.4.6.4.1. Market size and forecast, by Technology
8.4.6.4.2. Market size and forecast, by Formulation Type
8.4.6.4.3. Market size and forecast, by Disease Indication
8.4.6.4.4. Market size and forecast, by End User
8.4.6.5. South Korea
8.4.6.5.1. Market size and forecast, by Technology
8.4.6.5.2. Market size and forecast, by Formulation Type
8.4.6.5.3. Market size and forecast, by Disease Indication
8.4.6.5.4. Market size and forecast, by End User
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Market size and forecast, by Technology
8.4.6.6.2. Market size and forecast, by Formulation Type
8.4.6.6.3. Market size and forecast, by Disease Indication
8.4.6.6.4. Market size and forecast, by End User
8.5. LAMEA
8.5.1. Key market trends, growth factors and opportunities
8.5.2. Market size and forecast, by Technology
8.5.3. Market size and forecast, by Formulation Type
8.5.4. Market size and forecast, by Disease Indication
8.5.5. Market size and forecast, by End User
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Market size and forecast, by Technology
8.5.6.1.2. Market size and forecast, by Formulation Type
8.5.6.1.3. Market size and forecast, by Disease Indication
8.5.6.1.4. Market size and forecast, by End User
8.5.6.2. Saudi Arabia
8.5.6.2.1. Market size and forecast, by Technology
8.5.6.2.2. Market size and forecast, by Formulation Type
8.5.6.2.3. Market size and forecast, by Disease Indication
8.5.6.2.4. Market size and forecast, by End User
8.5.6.3. South Africa
8.5.6.3.1. Market size and forecast, by Technology
8.5.6.3.2. Market size and forecast, by Formulation Type
8.5.6.3.3. Market size and forecast, by Disease Indication
8.5.6.3.4. Market size and forecast, by End User
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Market size and forecast, by Technology
8.5.6.4.2. Market size and forecast, by Formulation Type
8.5.6.4.3. Market size and forecast, by Disease Indication
8.5.6.4.4. Market size and forecast, by End User
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product mapping of top 10 player
9.4. Competitive dashboard
9.5. Competitive heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. AbbVie Inc.
10.1.1. Company overview
10.1.2. Key executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.1.7. Key strategic moves and developments
10.2. Bausch Health Companies, Inc.
10.2.1. Company overview
10.2.2. Key executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.3. Ocular Therapeutix, Inc.
10.3.1. Company overview
10.3.2. Key executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.4. EyePoint Pharmaceuticals, Inc.
10.4.1. Company overview
10.4.2. Key executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.5. Clearside Biomedical, Inc.
10.5.1. Company overview
10.5.2. Key executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Key strategic moves and developments
10.6. Santen Pharmaceutical Co., Ltd.
10.6.1. Company overview
10.6.2. Key executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.7. Novaliq GmbH
10.7.1. Company overview
10.7.2. Key executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.8. Alimera Sciences, Inc.
10.8.1. Company overview
10.8.2. Key executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.9. Nocox
10.9.1. Company overview
10.9.2. Key executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.10. Kiora Pharmaceuticals, Inc.
10.10.1. Company overview
10.10.2. Key executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
